Ulrica Slåne Bjerke, chief invesment officer for the Arctic Aurora Lifescience fund, will attend the upcoming InvestmentEuorpe Nordic Summit Stockholm 2020 to discuss insights into lifescience developments and how investors can benefit from capturing value in healthcare innovation.
Arctic Aurora LifeScience is a global equity fund with an investment focus on innovative pharmaceutical and biotechnology companies, which are active in understanding human biology and genetics to develop faster and more precise medicines.
Growth in the sector is fast, and the fund is seeking to invest in new and clearly differentiated therapies focused on unmet medical needs. The investment team has vast experience in the pharmaceutical industry and equity management, as well as genuine technical insights into the scientific and medical matters that surround biotechology investments.
Ulrica Slåne Bjerke has 30 years of experience as an investment professional. Prior to founding Arctic Aurora LifeScience in 2016 she managed a biotech mandate at the Swedish pension fund AP3 for 10 years. Before joing AP3, Ulrica was a top-ranked sell-side healthcare analyst at Nordic investment banks including SEB Enskilda and Carnegie. Ulrica holds a MBASc from the Stockholm School of Economics, a CEFA and has studied medicine studies at Karolinska Institutet in Stockholm.
For full details of the Summit, visit: https://event.investmenteurope.net/nordicsummit/en/page/home